New experimental therapy in development for pancreatic cancer.
Posted by giorgiobertin on April 9, 2024
A new type of experimental therapy in development for pancreatic cancer has shown unprecedented tumor-fighting capabilities in preclinical models of the disease, suggesting it has the potential to offer new treatment options for nearly all pancreatic cancers.
Inhibitors in this new class of oral drugs, under development by Revolution Medicines Inc., target the active oncogenic or carcinogenic form of RAS proteins (such as KRAS, NRAS, and HRAS). These RAS “oncoproteins” cause up to a third of all human cancers.
“Thanks to the collaboration of a consortium of scientists on this problem, we were able to examine active RAS inhibition in all major classes of pancreatic cancer models, and this inhibitor worked really well in all of them.“, says the prof. Olives fromIrving Medical Center della Columbia University.
“RMC-7977 as a single agent outperformed the best combination regimen ever reported in the literature in that model system“.
While initial responses in preclinical tumor models to the inhibitor were impressive, Olive points out that the tumors were not eliminated. In cell culture, the investigators identified another oncogene, called MYC, that was altered in the majority of resistant tumors, and developed a combination treatment effective against tumor cells that had developed resistance to the active RAS inhibitor. These findings suggest a combinatorial approach worth exploring in patients in the future.
Read abstract of the article:
Tumor-selective activity of RAS-GTP inhibition in pancreatic cancer.
Wasko, U.N., Jiang, J., Dalton, T.C. et al.
Nature (2024).
Source: Irving Medical Center della Columbia University
This entry was posted on aprile 9, 2024 a 6:32 am and is filed under News-research. Tagged: pharmacology, Gastroenterology, oncology. You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a responseor trackback from your own site.